Biolidics Ltd. (SG:8YY)
SGX:8YY
Want to see SG:8YY full AI Analyst Report?
Top Page
Biolidics Ltd.
(SGX:8YY)
Select Model
Select Model
Rating:42Neutral
Price Target:
S$0.06
▲(40.00% Upside)
Action:ReiteratedDate:03/16/26
The score is held down primarily by weak financial performance—persistent losses, negative free cash flow, and limited balance-sheet flexibility—despite a strong 2025 revenue rebound. Technical indicators add caution due to negative MACD and below-average near-term price action, while valuation is difficult to assess meaningfully given negative earnings and no dividend yield data.
Positive Factors
Recurring consumable revenue
Biolidics sells test kits plus per-test consumables, creating a repeat-purchase revenue stream tied to installed usage. Over 2-6 months this dynamics supports steadier unit economics and revenue visibility as users continue buying consumables after initial instrument adoption.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow means the business does not yet self-fund its operations. Over the medium term this forces reliance on external financing or equity raises, which can dilute shareholders and limit ability to invest in commercialization or R&D if funding conditions tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumable revenue
Biolidics sells test kits plus per-test consumables, creating a repeat-purchase revenue stream tied to installed usage. Over 2-6 months this dynamics supports steadier unit economics and revenue visibility as users continue buying consumables after initial instrument adoption.
Read all positive factors
Biolidics Ltd. (8YY) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$88.41M
Dividend YieldN/A
Average Volume (3M)412.95K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS GrowthN/A
CountrySG
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,733,441,800
10 Day Avg. Volume410,990
30 Day Avg. Volume412,950
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)58.30
Price to Sales (P/S)16.93
P/FCF Ratio-247.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biolidics Ltd. Business Overview & Revenue Model
Company Description
Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Di...
How the Company Makes Money
Biolidics makes money primarily by selling diagnostic products and related consumables to healthcare providers, laboratories, distributors, and institutional buyers. Key revenue streams typically include (1) product sales of test kits (e.g., rapid...
Biolidics Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.26M | 784.00K | 277.00K | 2.49M | 2.31M |
| Gross Profit | 1.94M | 187.00K | 146.00K | 1.16M | 483.00K |
| EBITDA | -3.65M | -3.03M | -1.16M | -8.50M | -4.58M |
| Net Income | -3.96M | -3.43M | -2.49M | -9.37M | -5.98M |
Balance Sheet | |||||
| Total Assets | 5.08M | 4.67M | 682.00K | 6.09M | 11.42M |
| Cash, Cash Equivalents and Short-Term Investments | 557.00K | 295.00K | 183.00K | 5.03M | 3.96M |
| Total Debt | 2.41M | 1.75M | 2.02M | 3.01M | 4.25M |
| Total Liabilities | 3.56M | 2.94M | 2.67M | 7.78M | 9.09M |
| Stockholders Equity | 1.53M | 1.73M | -1.99M | -1.69M | 2.33M |
Cash Flow | |||||
| Free Cash Flow | -360.00K | -2.32M | -1.97M | -3.16M | -5.20M |
| Operating Cash Flow | -360.00K | -2.31M | -1.97M | -3.06M | -4.64M |
| Investing Cash Flow | 0.00 | -5.00K | -2.69M | 5.00K | -860.00K |
| Financing Cash Flow | 623.00K | 2.36M | -200.00K | 4.18M | -1.15M |
Biolidics Ltd. Technical Analysis
Positive
0.04
Price Trends
0.06
Positive
0.06
Positive
0.04
Positive
Market Momentum
<0.01
Negative
64.66
Neutral
36.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8YY, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 64.66 is Neutral, neither overbought nor oversold. The STOCH value of 36.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:8YY.
Biolidics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
SG:8YY
Biolidics Ltd.
0.05
0.03
168.42%
SG:P8A
Cordlife Group
0.15
0.00
0.00%
SG:40T
ISEC Healthcare Ltd
0.33
-0.02
-5.71%
SG:546
Medtecs International Corporation Ltd.
0.12
<0.01
2.65%
SG:584
AJJ Medtech Holdings Limited
0.01
0.00
0.00%
SG:9G2
Singapore Institute of Advanced Medicine Holdings Ltd.
0.04
<0.01
20.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.